| dc.contributor.author | Kekilli, Murat | |
| dc.contributor.author | Tanoğlu, Alpaslan | |
| dc.contributor.author | Kızıl Çakar, Merih | |
| dc.contributor.author | Güney, Güven | |
| dc.contributor.author | Haznedaroğlu, İbrahim C. | |
| dc.date.accessioned | 2019-05-13T09:08:35Z | |
| dc.date.available | 2019-05-13T09:08:35Z | |
| dc.date.issued | 2016 | |
| dc.identifier.citation | Kekilli, M., Tanoğlu, A., Kızıl Çakar, M., Güney, G., Haznedaroğlu, İ. C. (2016). Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemia. Uluslararasi Hematoloji Onkoloji Dergisi, 26(1), 67-68. | en_US |
| dc.identifier.issn | 1306-133X | |
| dc.identifier.uri | https://doi.org/10.4999/uhod.740 | |
| dc.identifier.uri | https://hdl.handle.net/11491/2019 | |
| dc.description.abstract | Dear Editor, Dasatinib is an orally administered, potent, secondline tyrosine kinase inhibitor which is used for treating imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. | en_US |
| dc.language.iso | eng | |
| dc.publisher | Akademi Doktorlar Yayınevi | en_US |
| dc.relation.isversionof | 10.4999/uhod.740 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | [Belirlenecek] | en_US |
| dc.title | Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemia | en_US |
| dc.type | other | en_US |
| dc.relation.journal | UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi | en_US |
| dc.department | Hitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
| dc.identifier.volume | 26 | en_US |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.startpage | 67 | en_US |
| dc.identifier.endpage | 68 | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
